04665nam 2201105z- 450 991056645740332120220506(CKB)5680000000037807(oapen)https://directory.doabooks.org/handle/20.500.12854/81056(oapen)doab81056(EXLCZ)99568000000003780720202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNew Therapies of Liver DiseasesBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (236 p.)3-0365-3859-3 3-0365-3860-7 In this Special Issue of the journal, advancements in the treatment of liver diseases are illustrated by international experts in the field. New treatment options for primary biliary cirrhosis and, hopefully, primary sclerosing cholangitis are discussed. Up-to-date pharmacological therapy for preventing liver cirrhosis decompensation and treating acute-on-chronic liver failure is highlighted. Furthermore, new treatments for cholangiocarcinoma, based on biological and tissue markers, will be available in the near future, aiming to surpass the current unsatisfactory results of traditional therapies. Immunotherapy has been applied to hepatocellular carcinoma (HCC). The new first-line treatment, combining atezolizumab plus bevacizumab for HCC in the intermediate and advanced stages, will allow for an increase in patient survival in the near future. Liver transplantation (LT) remains the preferred treatment for many patients with end-stage liver diseases and HCC. The selection criteria for LT in patients with HCC moved from morphological to dynamic criteria, such as those derived from the assessment of tumor responses to locoregional and/or systemic treatments before transplantation. This allowed many patients who would have been excluded from a transplantation with the old selection criteria to access one. Finally, a very interesting issue regarding new indications for liver transplantation is illustrated.Public health and preventive medicinebicsscacute-on-chronic liver failureacute-on-chronic liver failure (ACLF)alcoholic hepatitisalpha-fetoproteinammoniaanti-mineralocorticoidsantiviralsascitesautoantibodiesbleedingcholangiocarcinomacirrhosiscirrhotic ascitesclinical trialscolorectal cancer metastasesdecompensated cirrhosisdecompensationeffective hypovolemiaFarnesoid X Receptor (FXR) agonistfunctional curefurosemideHBVHDVhepatocellular carcinomahuman albuminhumoral responseimmunosuppressantimmunotherapyinfectionliver cancerliver injuryliver transplantationliver transplantation (LT)loop diureticsMilan criterian/anon-selective beta-blockersPan-Peroxisome Proliferator-Activated Receptor (PPAR) agonistspharmacologyportal hypertensionportal-systemic shuntprimary biliary cholangitisprimary biliary cholangitis (PBC)primary sclerosing cholangitis (PSC)real-worldrifaximinSARS-CoV-2second line therapysolid organ transplantationstatinssurvivalsurvival ratesystemic treatmenttargeted therapyTIPStolvaptantreatment responseunresectable hepatocellular carcinomaursodeoxycholic acidursodeoxycholic acid (UDCA)vaccinationvaptansvaricesvigilancePublic health and preventive medicineToniutto Pierluigiedt1319547Toniutto PierluigiothBOOK9910566457403321New Therapies of Liver Diseases3033951UNINA